Autolus Therapeutics - AUTL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.67
  • Forecasted Upside: 422.52 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.85
▼ -1.14 (-38.13%)

This chart shows the closing price for AUTL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Autolus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AUTL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUTL

Analyst Price Target is $9.67
▲ +422.52% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Autolus Therapeutics in the last 3 months. The average price target is $9.67, with a high forecast of $11.00 and a low forecast of $7.00. The average price target represents a 422.52% upside from the last price of $1.85.

This chart shows the closing price for AUTL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Autolus Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/15/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/9/2022Needham & Company LLCLower TargetBuy$12.00 ➝ $7.00Low
8/5/2022Needham & Company LLCLower TargetBuy$13.00 ➝ $12.00Low
6/14/2022Truist FinancialLower TargetBuy$13.00 ➝ $11.00High
3/10/2022William BlairReiterated RatingOutperformMedium
12/20/2021HC WainwrightReiterated RatingBuy$11.00Medium
8/2/2021MizuhoReiterated RatingBuy$18.00High
6/14/2021Jefferies Financial GroupUpgradeHold ➝ Buy$6.00 ➝ $12.00Low
5/6/2021Needham & Company LLCLower TargetBuy$26.00 ➝ $21.00Medium
3/16/2021Redburn PartnersReiterated RatingBuy ➝ NeutralHigh
3/10/2021Redburn PartnersDowngradeBuy ➝ NeutralLow
1/29/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$24.00 ➝ $9.00High
1/7/2021Truist FinancialLower Target$30.00 ➝ $15.00N/A
1/7/2021HC WainwrightLower TargetBuy$19.00 ➝ $13.00N/A
1/6/2021MizuhoReiterated RatingBuy$24.00N/A
12/28/2020HC WainwrightReiterated RatingBuy$19.00N/A
12/8/2020Needham & Company LLCReiterated RatingBuy$26.00High
11/25/2020Redburn PartnersInitiated CoverageBuyHigh
9/23/2020William BlairReiterated RatingBuyHigh
9/18/2020Needham & Company LLCReiterated RatingBuy$26.00High
8/6/2020MizuhoReiterated RatingBuy$24.00Low
7/31/2020JPMorgan Chase & Co.Initiated CoverageOverweight$25.00Low
7/22/2020SunTrust BanksInitiated CoverageBuy$38.00High
6/26/2020HC WainwrightReiterated RatingBuy$24.00Low
6/25/2020William BlairReiterated RatingBuyLow
6/19/2020MizuhoBoost TargetBuy$18.00 ➝ $24.00Medium
6/17/2020Jefferies Financial GroupReiterated RatingBuy$27.00Low
6/17/2020William BlairReiterated RatingBuyMedium
6/2/2020William BlairReiterated RatingBuyHigh
6/1/2020Needham & Company LLCInitiated CoverageBuy$26.00High
5/29/2020MizuhoReiterated RatingBuy$18.00High
5/8/2020HC WainwrightReiterated RatingBuyHigh
5/7/2020Needham & Company LLCReiterated RatingBuy$26.00High
4/21/2020MizuhoInitiated CoverageBuy$18.00High
12/9/2019HC WainwrightReiterated RatingBuy$24.00Low
11/8/2019HC WainwrightReiterated RatingBuyHigh
11/7/2019William BlairReiterated RatingBuyHigh
9/23/2019Needham & Company LLCInitiated CoverageBuy$26.00 ➝ $26.00Low
9/12/2019HC WainwrightReiterated RatingBuy$24.00Low
9/3/2019William BlairReiterated RatingBuyLow
5/17/2019HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $41.00Low
4/3/2019William BlairReiterated RatingBuyLow
2/20/2019HC WainwrightSet TargetBuy$45.00Medium
11/29/2018Wells Fargo & CompanyReiterated RatingBuy$38.00 ➝ $50.00Medium
11/2/2018HC WainwrightReiterated RatingBuy$45.00High
10/24/2018HC WainwrightInitiated CoverageBuy ➝ BuyMedium
7/26/2018The Goldman Sachs GroupInitiated CoverageNeutralLow
7/17/2018Wells Fargo & CompanyInitiated CoverageOutperform$38.00High
7/17/2018William BlairInitiated CoverageOutperformHigh
7/17/2018Jefferies Financial GroupInitiated CoverageBuy$37.00High
(Data available from 12/10/2017 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/13/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/12/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/11/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/11/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/10/2022
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/10/2022

Current Sentiment

  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Autolus Therapeutics logo
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $1.85
Low: $1.79
High: $2.00

50 Day Range

MA: $2.72
Low: $1.85
High: $3.27

52 Week Range

Now: $1.85
Low: $1.79
High: $6.92

Volume

11,262,544 shs

Average Volume

280,423 shs

Market Capitalization

$168.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Autolus Therapeutics?

The following Wall Street research analysts have issued research reports on Autolus Therapeutics in the last year: HC Wainwright, Needham & Company LLC, Truist Financial Co., and William Blair.
View the latest analyst ratings for AUTL.

What is the current price target for Autolus Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Autolus Therapeutics in the last year. Their average twelve-month price target is $9.67, suggesting a possible upside of 422.5%. Truist Financial Co. has the highest price target set, predicting AUTL will reach $11.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $7.00 for Autolus Therapeutics in the next year.
View the latest price targets for AUTL.

What is the current consensus analyst rating for Autolus Therapeutics?

Autolus Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AUTL will outperform the market and that investors should add to their positions of Autolus Therapeutics.
View the latest ratings for AUTL.

What other companies compete with Autolus Therapeutics?

Other companies that are similar to Autolus Therapeutics include VectivBio, ProKidney, MeiraGTx, Opthea and Fennec Pharmaceuticals. Learn More about companies similar to Autolus Therapeutics.

How do I contact Autolus Therapeutics' investor relations team?

Autolus Therapeutics' physical mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company's listed phone number is 442038296230 and its investor relations email address is [email protected] The official website for Autolus Therapeutics is www.autolus.com. Learn More about contacing Autolus Therapeutics investor relations.